Concepts (114)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Coagulation Disorders | 4 | 2023 | 66 | 2.510 |
Why?
|
| Thrombelastography | 4 | 2023 | 47 | 1.360 |
Why?
|
| Hemorrhage | 3 | 2024 | 284 | 1.200 |
Why?
|
| Erythrocyte Transfusion | 4 | 2024 | 73 | 1.050 |
Why?
|
| Anemia, Sickle Cell | 3 | 2024 | 144 | 1.040 |
Why?
|
| Hypocalcemia | 1 | 2024 | 44 | 0.940 |
Why?
|
| Blood Coagulation | 2 | 2023 | 91 | 0.910 |
Why?
|
| Thrombosis | 2 | 2023 | 301 | 0.870 |
Why?
|
| Blood Group Antigens | 1 | 2022 | 17 | 0.800 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2022 | 14 | 0.800 |
Why?
|
| Wounds and Injuries | 1 | 2024 | 260 | 0.760 |
Why?
|
| Catheterization, Central Venous | 1 | 2022 | 114 | 0.750 |
Why?
|
| Placenta | 1 | 2022 | 181 | 0.730 |
Why?
|
| Calcium | 1 | 2024 | 1179 | 0.670 |
Why?
|
| Abdominal Wall | 1 | 2019 | 30 | 0.670 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2019 | 81 | 0.640 |
Why?
|
| Blood Transfusion | 3 | 2024 | 171 | 0.610 |
Why?
|
| Amyloidosis | 1 | 2019 | 130 | 0.600 |
Why?
|
| Sarcoma | 1 | 2019 | 219 | 0.590 |
Why?
|
| Oxygen | 1 | 2022 | 745 | 0.560 |
Why?
|
| Insulin | 1 | 2019 | 1148 | 0.470 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2020 | 798 | 0.460 |
Why?
|
| Blood Coagulation Tests | 2 | 2023 | 35 | 0.440 |
Why?
|
| Melanoma | 3 | 2021 | 471 | 0.400 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 1180 | 0.370 |
Why?
|
| Erythrocytes | 2 | 2022 | 254 | 0.370 |
Why?
|
| Specimen Handling | 2 | 2022 | 103 | 0.360 |
Why?
|
| Uveal Neoplasms | 2 | 2021 | 11 | 0.360 |
Why?
|
| Humans | 22 | 2024 | 89785 | 0.340 |
Why?
|
| Neoplasms | 2 | 2022 | 3062 | 0.340 |
Why?
|
| Isoantibodies | 3 | 2024 | 120 | 0.280 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2022 | 952 | 0.280 |
Why?
|
| Hemoglobins | 2 | 2024 | 193 | 0.270 |
Why?
|
| Citric Acid | 1 | 2024 | 44 | 0.240 |
Why?
|
| Hypercalcemia | 1 | 2024 | 63 | 0.230 |
Why?
|
| Transfusion Reaction | 1 | 2024 | 17 | 0.230 |
Why?
|
| Neoplasm Metastasis | 4 | 2021 | 1066 | 0.220 |
Why?
|
| Tissue Fixation | 1 | 2022 | 40 | 0.200 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 2022 | 18 | 0.200 |
Why?
|
| Paraffin Embedding | 1 | 2022 | 78 | 0.200 |
Why?
|
| Formaldehyde | 1 | 2022 | 52 | 0.200 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2021 | 13 | 0.190 |
Why?
|
| Plasma Exchange | 1 | 2021 | 30 | 0.190 |
Why?
|
| Catheters, Indwelling | 1 | 2022 | 114 | 0.190 |
Why?
|
| Lymphoma, B-Cell | 1 | 2022 | 107 | 0.190 |
Why?
|
| Ipilimumab | 1 | 2021 | 60 | 0.190 |
Why?
|
| 5-Methylcytosine | 1 | 2022 | 117 | 0.180 |
Why?
|
| Shear Strength | 1 | 2020 | 18 | 0.180 |
Why?
|
| Device Approval | 1 | 2020 | 13 | 0.180 |
Why?
|
| Fibrinogen | 1 | 2020 | 53 | 0.180 |
Why?
|
| Indicators and Reagents | 1 | 2020 | 72 | 0.180 |
Why?
|
| Viscosity | 1 | 2020 | 46 | 0.180 |
Why?
|
| Fibrinolysis | 1 | 2020 | 37 | 0.180 |
Why?
|
| Elasticity | 1 | 2020 | 97 | 0.180 |
Why?
|
| Vibration | 1 | 2020 | 50 | 0.180 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2020 | 46 | 0.180 |
Why?
|
| Blood Platelets | 1 | 2020 | 150 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 2505 | 0.170 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 135 | 0.170 |
Why?
|
| Injections, Subcutaneous | 1 | 2019 | 122 | 0.170 |
Why?
|
| Vaccination | 1 | 2021 | 278 | 0.160 |
Why?
|
| Anemia | 1 | 2020 | 132 | 0.160 |
Why?
|
| Equipment Design | 1 | 2020 | 421 | 0.160 |
Why?
|
| Ophthalmology | 1 | 2019 | 44 | 0.160 |
Why?
|
| Mouth Diseases | 1 | 2018 | 16 | 0.160 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2019 | 160 | 0.150 |
Why?
|
| Choristoma | 1 | 2018 | 68 | 0.150 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 306 | 0.150 |
Why?
|
| Stomach | 1 | 2018 | 111 | 0.150 |
Why?
|
| Cysts | 1 | 2018 | 106 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2024 | 889 | 0.140 |
Why?
|
| Radiosurgery | 1 | 2020 | 287 | 0.140 |
Why?
|
| Male | 7 | 2024 | 42582 | 0.130 |
Why?
|
| Adult | 4 | 2024 | 26767 | 0.130 |
Why?
|
| Female | 7 | 2024 | 46494 | 0.130 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 598 | 0.130 |
Why?
|
| Retrospective Studies | 3 | 2024 | 9159 | 0.120 |
Why?
|
| Middle Aged | 6 | 2024 | 26080 | 0.120 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 1542 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 1283 | 0.120 |
Why?
|
| Intestines | 1 | 2018 | 416 | 0.120 |
Why?
|
| Pregnancy | 1 | 2022 | 3040 | 0.120 |
Why?
|
| Registries | 1 | 2019 | 792 | 0.120 |
Why?
|
| Phenotype | 1 | 2020 | 2450 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 1134 | 0.110 |
Why?
|
| Mutation | 2 | 2022 | 4164 | 0.100 |
Why?
|
| Aged | 3 | 2021 | 19212 | 0.080 |
Why?
|
| United States | 1 | 2020 | 7083 | 0.070 |
Why?
|
| Blood Substitutes | 1 | 2024 | 8 | 0.060 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 2024 | 14 | 0.060 |
Why?
|
| Hemolysis | 1 | 2022 | 64 | 0.050 |
Why?
|
| Platelet Factor 4 | 1 | 2021 | 12 | 0.050 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2023 | 172 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2024 | 995 | 0.050 |
Why?
|
| Platelet Count | 1 | 2021 | 93 | 0.050 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2024 | 399 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 6778 | 0.040 |
Why?
|
| Anilides | 1 | 2019 | 45 | 0.040 |
Why?
|
| Peer Review | 1 | 2019 | 23 | 0.040 |
Why?
|
| Publications | 1 | 2019 | 27 | 0.040 |
Why?
|
| Dacarbazine | 1 | 2019 | 101 | 0.040 |
Why?
|
| Transfection | 1 | 2021 | 909 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2023 | 2018 | 0.040 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 203 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 521 | 0.040 |
Why?
|
| Pyridines | 1 | 2019 | 300 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 1496 | 0.040 |
Why?
|
| Survival Rate | 1 | 2020 | 1890 | 0.030 |
Why?
|
| Research Design | 1 | 2019 | 591 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 860 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 1451 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 1729 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 3785 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2018 | 2498 | 0.020 |
Why?
|